Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

被引:241
作者
Ishida, Takashi
Ishii, Toshihiko
Inagaki, Atsushi
Yano, Hiroki
Komatsu, Hirokazu
Iida, Shinsuke
Inagaki, Hiroshi
Ueda, Ryuzo
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Pathol, Mizuho Ku, Nagoya, Aichi 4678601, Japan
关键词
D O I
10.1158/0008-5472.CAN-06-0261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hodgkin lymphoma (HL) is characterized by the presence of a small number of tumor cells in a rich background of inflammatory cells, but the contribution of the abundant nontumor cells to HL pathogenesis is poorly understood. We showed that migratory CD4(+) cells induced by HL cells were hyporesponsive to T-cell receptor stimulation and suppressed the activation/proliferation of the effector CD4(+) T cells in an autologous setting. We further showed that HL cells in the affected lymph nodes were surrounded by a large number of lymphocytes expressing both CC chemokine receptor 4 (CCR4) and FOXP3. These findings indicate that the migratory cells induced by HL cells function as regulatory T (Treg) cells so that these cells create a favorable environment for the tumor cells to escape from host immune system. In addition, we showed that a chimeric anti-CCR4 monoclonal antibody (mAb) could deplete CCR4(+) T cells and inhibit the migration of CD4(+)CD25(+) T cells in vitro. Recognition of the importance of CCR4(+) Treg cells in the pathogenesis of HL will allow rational design of more effective treatments, such as use of an anti-CCR4 mAb, to overcome the suppressive effect of CCR4(+) Treg cells on the host immune response to tumor cells.
引用
收藏
页码:5716 / 5722
页数:7
相关论文
共 36 条
  • [1] [Anonymous], WHO CLASSIFICATION T
  • [2] Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Beyer, M
    Kochanek, M
    Darabi, K
    Popov, A
    Jensen, M
    Endl, E
    Knolle, PA
    Thomas, RK
    von Bergwelt-Baildon, M
    Bebey, S
    Hallek, M
    Schultze, JL
    [J]. BLOOD, 2005, 106 (06) : 2018 - 2025
  • [3] Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
    Bollard, CM
    Aguilar, L
    Straathof, KC
    Gahn, B
    Huls, MH
    Rousseau, A
    Sixbey, J
    Gresik, MV
    Carrum, G
    Hudson, M
    Dilloo, D
    Gee, A
    Brenner, MK
    Rooney, CM
    Heslop, HE
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12) : 1623 - 1633
  • [4] Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
    Bonecchi, R
    Bianchi, G
    Bordignon, PP
    D'Ambrosio, D
    Lang, R
    Borsatti, A
    Sozzani, S
    Allavena, P
    Gray, PA
    Mantovani, A
    Sinigaglia, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) : 129 - 134
  • [5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [6] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Curiel, TJ
    Coukos, G
    Zou, LH
    Alvarez, X
    Cheng, P
    Mottram, P
    Evdemon-Hogan, M
    Conejo-Garcia, JR
    Zhang, L
    Burow, M
    Zhu, Y
    Wei, S
    Kryczek, I
    Daniel, B
    Gordon, A
    Myers, L
    Lackner, A
    Disis, ML
    Knutson, KL
    Chen, LP
    Zou, WP
    [J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949
  • [7] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    Dannull, J
    Su, Z
    Rizzieri, D
    Yang, BK
    Coleman, D
    Yancey, D
    Zhang, AJ
    Dahm, P
    Chao, N
    Gilboa, E
    Vieweg, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) : 3623 - 3633
  • [8] Ghia P, 2002, EUR J IMMUNOL, V32, P1403, DOI 10.1002/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO
  • [9] 2-Y
  • [10] Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
    Gottschalk, S
    Edwards, OL
    Sili, U
    Huls, MH
    Goltsova, T
    Davis, AR
    Heslop, HE
    Rooney, CM
    [J]. BLOOD, 2003, 101 (05) : 1905 - 1912